Certain patients with inflammatory bowel disease are at heightened risk for the development of colorectal cancer. But researchers have not yet been able to discover markers that can identify these patients.
Certain patients with inflammatory bowel disease (IBD) are at heightened risk for the development of colorectal cancer. But researchers have not yet been able to discover markers that can identify these patients.1
In a retrospective review of electronic medical records at the University of Pennsylvania Hospital in Philadelphia, investigators found that 4 patients with chronic IBD out of 258 who had undergone colectomy or colonoscopy with biopsy had premalignant serrated adenomas. Three of the patients with these lesions had Crohn disease, and one had ulcerative colitis.2
The investigators cautioned that further research is needed to determine the implications of the presence of serrated adenomas for the future risk of colorectal cancer.
REFERENCES:
1. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738-745.
2. Blonski W, Dumoff K, Sonu I, et al. Prevalence and characteristics of patients with IBD who develop serrated adenomas. Am J Gastroenterol. 2010;105(suppl 1):S440-S441.
Clinical Tips for Using Antibiotics and Corticosteroids in IBD
January 5th 2013The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.